N/A
Manufactured by Key Therapeutics
1,335 FDA adverse event reports analyzed
Last updated: 2026-04-15
IMIPRAMINE HYDROCHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Key Therapeutics. The most commonly reported adverse reactions for IMIPRAMINE HYDROCHLORIDE include OFF LABEL USE, DIZZINESS, DRUG INEFFECTIVE, FATIGUE, HYPERTENSION. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for IMIPRAMINE HYDROCHLORIDE.
Out of 537 classified reports for IMIPRAMINE HYDROCHLORIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 1,335 FDA FAERS reports that mention IMIPRAMINE HYDROCHLORIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include OFF LABEL USE, DIZZINESS, DRUG INEFFECTIVE, FATIGUE, HYPERTENSION, ANXIETY. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Key Therapeutics in connection with IMIPRAMINE HYDROCHLORIDE. Always verify the specific product and NDC with your pharmacist.